×
Jeśli w ciągu kilku sekund nie nastąpi przekierowanie, kliknij
tutaj
.
Wszystko
Grafika
Wideo
Wiadomości
Mapy
Zakupy
Książki
Narzędzia wyszukiwania
Szukaj w internecie
Szukaj w internecie
Tylko język polski
Najnowsze
Najnowsze
Ostatnia godzina
Ostatnie 24 godziny
Ostatni tydzień
Ostatni miesiąc
Ostatni rok
Archiwa
Według trafności
Według trafności
Według daty
FDA Grants Fast Track Designation to Amolyt Pharma's Eneboparatide to Treat Hypoparathyroidism
Pharmaceutical Executive
“We believe FDA's granting of fast-track designation to eneboparatide reflects the agency's recognition of the significant unmet needs that...
3 tygodnie temu
FDA puts off decision to approve hypoparathyroidism drug TransCon PTH
Hypoparathyroidism News
Regulators have approved TransCon PTH for hypoparathyroidism in the European Union and Great Britain, where it is available as Yorvipath.
6 dni temu
Here's one rare disease we can address tomorrow: Hypoparathyroidism
www.statnews.com
HypoPARA can be associated with severe life-threatening conditions such as laryngospasm, tetany, and seizure, but what is underrecognized are...
miesiąc temu
Ozempic Price Cut; Hypoparathyroidism Tx Fast Tracked; Halle Berry's Menopause Bill
MedPage Today
News and commentary from the endocrinology world.
2 tygodnie temu
FDA Delays Review by Three Months for Ascendis’ Hypoparathyroidism Therapy
BioSpace
Following an initial rejection in 2023, Ascendis Pharma on Tuesday said it faces another regulatory bump in the road for TransCon PTH with a...
tydzień temu
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
Fierce Pharma
It's been a long wait for Ascendis to score FDA approval for its hormone replacement therapy TransCon PTH. Now, it'll take another three...
tydzień temu
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of ...
Yahoo Finance
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of...
tydzień temu
Fahr syndrome and neurological manifestations in hypoparathyroidism patients
ScienceDirect.com
One of the most common causes of Fahr syndrome is hypoparathyroidism. Physiologically, the parathyroid glands secrete parathyroid hormone (PTH) to regulate...
4 miesiące temu
AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda
MedCity News
AstraZeneca is bolstering its rare disease pipeline with a deal to buy Amolyt Pharma, a biotech company in late-stage development with a...
2 miesiące temu
FDA to Review Resubmitted NDA for Hypoparathyroidism Med TransCon PTH
Endocrinology Advisor
The FDA has accepted for review the resubmitted New Drug Application for TransCon PTH (palopegteriparatide) for the treatment of...
5 miesięcy temu